

Zhe Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7367093/publications.pdf>

Version: 2024-02-01

34
papers

1,269
citations

394421

19
h-index

434195

31
g-index

35
all docs

35
docs citations

35
times ranked

2219
citing authors

#	ARTICLE	IF	CITATIONS
1	CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 345-355.	4.4	2
2	Preclinical models of pancreatic ductal adenocarcinoma: challenges and opportunities in the era of precision medicine. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 8.	8.6	13
3	The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells. <i>Cells</i> , 2021, 10, 497.	4.1	28
4	Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models. <i>Clinical Cancer Research</i> , 2021, 27, 3383-3396.	7.0	36
5	A randomised, multicentre trial of somatostatin to prevent clinically relevant postoperative pancreatic fistula in intermediate-risk patients after pancreaticoduodenectomy. <i>Journal of Gastroenterology</i> , 2021, 56, 938-948.	5.1	8
6	Risk factors of systematic biliary complications in patients with gallbladder stones. <i>Irish Journal of Medical Science</i> , 2020, 189, 943-947.	1.5	1
7	MicroRNA-381 A Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 535665.	2.8	4
8	The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094094.	3.2	35
9	Mechanistic target of rapamycin in the tumor microenvironment and its potential as a therapeutic target for pancreatic cancer. <i>Cancer Letters</i> , 2020, 485, 1-13.	7.2	10
10	Expression, function and clinical application of stanniocalcin-1 in cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7686-7696.	3.6	31
11	Novel therapeutic strategies and perspectives for metastatic pancreatic cancer: vaccine therapy is more than just a theory. <i>Cancer Cell International</i> , 2020, 20, 66.	4.1	27
12	OLR1 Promotes Pancreatic Cancer Metastasis via Increased c-Myc Expression and Transcription of HMGA2. <i>Molecular Cancer Research</i> , 2020, 18, 685-697.	3.4	40
13	Novel Discoveries Targeting Pathogenic Gut Microbes and New Therapies in Pancreatic Cancer: Does Pathogenic <i>E. coli</i> Infection Cause Pancreatic Cancer Progression Modulated by TUBB/Rho/ROCK Signaling Pathway? A Bioinformatic Analysis. <i>BioMed Research International</i> , 2020, 2020, 1-12.	1.9	10
14	Is Invagination Anastomosis More Effective in Reducing Clinically Relevant Pancreatic Fistula for Soft Pancreas After Pancreaticoduodenectomy Under Novel Fistula Criteria: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 1637.	2.8	7
15	Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?. <i>Cancer Medicine</i> , 2019, 8, 6403-6413.	2.8	17
16	MicroRNA-27a (miR-27a) in Solid Tumors: A Review Based on Mechanisms and Clinical Observations. <i>Frontiers in Oncology</i> , 2019, 9, 893.	2.8	41
17	The dual functional role of MicroRNA-18a (miR-18a) in cancer development. <i>Clinical and Translational Medicine</i> , 2019, 8, 32.	4.0	55
18	Role of the microbiome in occurrence, development and treatment of pancreatic cancer. <i>Molecular Cancer</i> , 2019, 18, 173.	19.2	67

#	ARTICLE	IF	CITATIONS
19	Pancreatic head cancer: Open or minimally invasive pancreaticoduodenectomy?. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 862-877.	2.2	2
20	Glucagonoma and the glucagonoma syndrome (Review). Oncology Letters, 2018, 15, 2749-2755.	1.8	38
21	NF- κ B in pancreatic cancer: Its key role in chemoresistance. Cancer Letters, 2018, 421, 127-134.	7.2	71
22	LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer. Journal of Experimental and Clinical Cancer Research, 2018, 37, 274.	8.6	83
23	Extracellular vesicles as mediators of the progression and chemoresistance of pancreatic cancer and their potential clinical applications. Molecular Cancer, 2018, 17, 2.	19.2	61
24	The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer. Cancer Letters, 2017, 397, 94-102.	7.2	50
25	PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Letters, 2017, 407, 57-65.	7.2	235
26	PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value. Journal of Experimental and Clinical Cancer Research, 2016, 35, 133.	8.6	46
27	miR-497 expression, function and clinical application in cancer. Oncotarget, 2016, 7, 55900-55911.	1.8	57
28	CHIP: A new modulator of human malignant disorders. Oncotarget, 2016, 7, 29864-29874.	1.8	31
29	Analysis of clinical characteristics and treatment of pancreatic cystic tumors. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 519-527.	2.2	0
30	Localized Autoimmune Pancreatitis. Medicine (United States), 2015, 94, e1656.	1.0	18
31	MiR-1178 Promotes the Proliferation, G1/S Transition, Migration and Invasion of Pancreatic Cancer Cells by Targeting CHIP. PLoS ONE, 2015, 10, e0116934.	2.5	19
32	Surgical treatment of pancreatic head cancer: concept revolutions and arguments. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2015, 27, 392-6.	2.2	4
33	MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis. Oncotarget, 2014, 5, 6983-6993.	1.8	76
34	Plasma microRNA panels to diagnose pancreatic cancer: Results from a multicenter study. Oncotarget, 0, 7, 41575-41583.	1.8	46